Executives and guests of Dublin-based Covidien will visit the New York Stock Exchange (NYSE) to celebrate the successful spinoff of its Mallinckrodt pharmaceuticals business. (NYSE: MNK). To mark this occasion, José (Joe) E. Almeida, Chairman, President and Chief Executive Officer of Covidien plc, will ring The NYSE Closing Bell, joined by members of the company's management team. Covidien will complete the distribution of Mallinckrodt ordinary shares after the close of trading on the NYSE on June 28, 2013. On July 1, 2013, regular-way trading will commence on the NYSE for Mallinckrodt under the symbol "MNK" and will continue for Covidien under the symbol "COV." ABOUT COVIDIEN (NYSE: COV) Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.
Geratherm Medical AG is a medical technology company, which engages in the manufacture and distribution of medical technology products for...
Sectra AB conducts development and sales of cutting edge solutions in expanding niche segments. Current operations include medical systems and...
20 on Hatch Lower Hatch Street
Dublin , DU 2
SIC Code: 3841